ribociclib,Abemaciclib,olaparib
novartis,eli lilly,AstraZeneca,Merck
['bcsm', ' ribo']
fantastic discussion about adjuvant cdk4/6 inhibitor trials - assuming ribo is approved, how will we select patients that can derive a benefit from 3 years of cdk4/6 inhibitors? #asco23 #bcsm 
Breast medical oncologist @TuftsMedicalCtr | Tweets are my own and not medical advice | 🇲🇽